Rhumbline Advisers purchased a new stake in shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) in the 2nd quarter, Holdings Channel reports. The fund purchased 83,982 shares of the biotechnology company’s stock, valued at approximately $1,142,000.
Several other institutional investors also recently bought and sold shares of ARWR. Trexquant Investment LP bought a new stake in shares of Arrowhead Pharmaceuticals during the first quarter valued at approximately $139,000. Quantitative Systematic Strategies LLC bought a new position in Arrowhead Pharmaceuticals in the first quarter worth approximately $100,000. Schwab Charles Investment Management Inc. raised its stake in Arrowhead Pharmaceuticals by 46.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 273,042 shares of the biotechnology company’s stock worth $1,969,000 after buying an additional 86,661 shares in the last quarter. ClariVest Asset Management LLC bought a new position in Arrowhead Pharmaceuticals in the first quarter worth approximately $507,000. Finally, Northern Trust Corp raised its stake in Arrowhead Pharmaceuticals by 12.7% in the first quarter. Northern Trust Corp now owns 221,517 shares of the biotechnology company’s stock worth $1,597,000 after buying an additional 24,932 shares in the last quarter. 58.96% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:ARWR opened at $18.91 on Monday. The company has a market capitalization of $1.68 billion, a P/E ratio of -40.23 and a beta of 1.91. Arrowhead Pharmaceuticals Inc has a 52 week low of $2.75 and a 52 week high of $22.39. The company has a quick ratio of 8.69, a current ratio of 8.69 and a debt-to-equity ratio of 0.02.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. The company had revenue of $0.73 million during the quarter, compared to the consensus estimate of $0.62 million. Arrowhead Pharmaceuticals had a negative net margin of 400.13% and a negative return on equity of 59.39%. sell-side analysts predict that Arrowhead Pharmaceuticals Inc will post -0.64 EPS for the current fiscal year.
In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 45,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $19.34, for a total value of $870,300.00. Following the transaction, the chief financial officer now directly owns 335,815 shares of the company’s stock, valued at $6,494,662.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher Richard Anzalone sold 100,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, August 31st. The stock was sold at an average price of $14.45, for a total transaction of $1,445,000.00. Following the completion of the transaction, the chief executive officer now directly owns 1,868,789 shares in the company, valued at $27,004,001.05. The disclosure for this sale can be found here. Insiders sold 329,834 shares of company stock worth $4,977,351 over the last ninety days. Corporate insiders own 4.60% of the company’s stock.
A number of equities analysts recently commented on ARWR shares. Cantor Fitzgerald reissued a “buy” rating and issued a $13.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, May 30th. BidaskClub raised shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 2nd. S&P Equity Research reduced their price objective on shares of Arrowhead Pharmaceuticals from $13.76 to $11.68 in a research note on Monday, June 18th. Piper Jaffray Companies reissued an “overweight” rating and issued a $17.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Friday, June 29th. Finally, Chardan Capital boosted their price objective on shares of Arrowhead Pharmaceuticals from $9.50 to $16.00 and gave the stock a “buy” rating in a research note on Monday, July 2nd. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $19.03.
Arrowhead Pharmaceuticals Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Read More: What is the NASDAQ?
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.